Tardiness in spl, page-16

I think there is only1 possible answer. The intention was to launch in Australia and then this got delayed because another approval was needed (which we saw). Now they are holding back the launch deliberately. Perhaps they thought it would only be held back a few months while other ducks were lined up, but everything has taken longer than expected.

Possible reasons for delaying Australian launch:
1. Regulatory or sign off issues - highly unlikely because they were so close and so confident.
2. Strategic because they are wanting to launch elsewhere first. The idea of launching first in the US to set a high price point makes no business sense because it would hold everything back until Q1 2019 and otc here is different to prescription basis there.
3. They are looking to sell off the Vivagel for BV product to another company. In this case, it may make sense to hand it over ready to launch worldwide and not start selling it prior, and build the foregone sales into the selling price. This sale may be depending on the FDA approval and would be too sensitive to announce to the market.
4. Their main game is to sell SPL altogether and again they are delaying launch to keep it clean and maybe give Astra Zeneca or some major Pharma buyer the opportunity to launch it all under their own brand.
5. There’s some awful stuff up that we don’t know about

I feel that the most likely scenario is a strategic holding back so it launches worldwide and they don’t suffer gray imports into the US (eg the baby formula to China situation).

I’m very keen to hear others’ thought on this.

I bought some more today because I think their release next week will be received positively. My second reason is to follow the money. In hindsight it will seem obvious that someone is piling in for a reason and we have a week to do likewise. IMO only, I hope I’m right about this!